Squarepoint’s Sophiris Bio, Inc. SPHS Stock Holding History

Squarepoint’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,800	Closed	-$28K	–	2257
2018 Q1	$28K	Buy	+13,800	New	+$29.9K	﹤0.01%	1624
2017 Q3	–	Sell	-83,100	Closed	-$183K	–	2072
2017 Q2	$183K	Sell	83,100 -5,500	-6%	-$13.5K	﹤0.01%	1322
2017 Q1	$251K	Hold	88,600	–	–	0.01%	1180
2016 Q4	$248K	Buy	+88,600	New	+$251K	0.01%	1274

Other funds holding SPHS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return

ACM

Alpha Capital Management Austin, Texas $690M AUM 22.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Squarepoint's SPHS Position: Q2 2018 in Review

Squarepoint sold out of Sophiris Bio, Inc. (SPHS) in Q2 2018, closing a stake of 13,800 shares — an estimated $28K sold.

Squarepoint first reported a position in SPHS in Q4 2016 and held it in 4 quarters. The position peaked at $251K in Q1 2017. 30 funds tracked by Wall St. Rank hold SPHS as of Q2 2018.

Squarepoint reported no remaining Sophiris Bio, Inc. position as of Q2 2018 after selling out during the quarter.
Squarepoint sold 13,800 Sophiris Bio, Inc. shares in Q2 2018, an estimated $28K.
Squarepoint first reported a position in Sophiris Bio, Inc. in Q4 2016 and held it in 4 quarters.
Squarepoint's Sophiris Bio, Inc. position peaked at $251K in Q1 2017.
30 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q2 2018.

Based on Squarepoint's 13F filing for Q2 2018, filed 14 Aug 2018.